Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Maintenance Versus Observation With 6 Cycles of Gemcitabine Plus Taxol Sequential Gemcitabine Single Agent in Patients With Metastatic Breast Cancer

NCT02188693 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT02188693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02188693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Maintenance Versus Observation With 6 Cycles of Gemcitabine Plus Taxol Sequential Gemcitabine Single Agent in Patients With Metastatic Breast Cancer
Lead sponsor
Xijing Hospital
Phase
Observational
Overall status
Unknown status
Start date
July 31, 2014
Completion date
December 31, 2017
Enrollment
267 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gemcitabine, maintenance chemotherapy, stage iiib, iv, recurrent, and metastatic breast cancer